Ligand Pharmaceuticals (LGND) EPS (Basic) (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted EPS (Basic) of -$0.67 for Q1 2026, down 128.98% sequentially from $2.32 in Q4 2025, and up 69.66% YoY from -$0.4 in Q1 2025.
Powered by 
Analysis
Ligand Pharmaceuticals (LGND) EPS (Basic) (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported EPS (Basic) for 15 years, with the latest figure at -$0.67 in Q1 2026.
- Quarterly EPS (Basic) rose 69.66% year-over-year to -$0.67 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.72 (up 301.55% YoY) and the FY2025 annual result came in at $6.44, up 3019.36% from the prior year.
- EPS (Basic) declined to -$0.67 in Q1 2026 per LGND's latest filing, from $2.32 in the prior quarter.
- Over five years, EPS (Basic) peaked at $5.99 in Q3 2025 and troughed at -$2.21 in Q1 2025.
- A 5-year average of $0.2 and a median of -$0.17 in 2022 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2025: EPS (Basic) tumbled 133.11% in 2022, then jumped 236.25% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.17 in 2022, then jumped by 44.22% to -$0.1 in 2023, then slumped by 1641.89% to -$1.7 in 2024, then surged by 236.25% to $2.32 in 2025, then sank by 128.98% to -$0.67 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.67, $2.32, and $5.99 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | Ligand Pharmaceuticals | 5.77 Bn | 4.41 Bn | 60.48 Mn | 2.42 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.42 |
| Mar 31, 2026 | -0.67 |
| Dec 31, 2025 | 2.32 |
| Sep 30, 2025 | 5.99 |
| Jun 30, 2025 | 0.25 |
| Mar 31, 2025 | -2.21 |
| Dec 31, 2024 | -1.70 |
| Sep 30, 2024 | -0.39 |
| Jun 30, 2024 | -2.88 |
| Mar 31, 2024 | 4.86 |
| Dec 31, 2023 | 1.05 |
| Sep 30, 2023 | -0.59 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | 2.46 |
| Dec 31, 2022 | -1.04 |
| Sep 30, 2022 | 0.02 |
| Jun 30, 2022 | -0.05 |
| Mar 31, 2022 | -0.91 |
| Dec 31, 2021 | 0.70 |
| Sep 30, 2021 | 0.43 |